320 related articles for article (PubMed ID: 31866294)
1. Structural Basis of the Interaction Between Ubiquitin Specific Protease 7 and Enhancer of Zeste Homolog 2.
Gagarina V; Bojagora A; Lacdao IK; Luthra N; Pfoh R; Mohseni S; Chaharlangi D; Tan N; Saridakis V
J Mol Biol; 2020 Feb; 432(4):897-912. PubMed ID: 31866294
[TBL] [Abstract][Full Text] [Related]
2. Bimodal regulation of the PRC2 complex by USP7 underlies tumorigenesis.
Su D; Wang W; Hou Y; Wang L; Yi X; Cao C; Wang Y; Gao H; Wang Y; Yang C; Liu B; Chen X; Wu X; Wu J; Yan D; Wei S; Han L; Liu S; Wang Q; Shi L; Shan L
Nucleic Acids Res; 2021 May; 49(8):4421-4440. PubMed ID: 33849069
[TBL] [Abstract][Full Text] [Related]
3. Bach1 regulates self-renewal and impedes mesendodermal differentiation of human embryonic stem cells.
Wei X; Guo J; Li Q; Jia Q; Jing Q; Li Y; Zhou B; Chen J; Gao S; Zhang X; Jia M; Niu C; Yang W; Zhi X; Wang X; Yu D; Bai L; Wang L; Na J; Zou Y; Zhang J; Zhang S; Meng D
Sci Adv; 2019 Mar; 5(3):eaau7887. PubMed ID: 30891497
[TBL] [Abstract][Full Text] [Related]
4. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.
Mu W; Starmer J; Yee D; Magnuson T
Epigenetics Chromatin; 2018 Dec; 11(1):71. PubMed ID: 30522506
[TBL] [Abstract][Full Text] [Related]
5. Regulation of histone methylation by automethylation of PRC2.
Wang X; Long Y; Paucek RD; Gooding AR; Lee T; Burdorf RM; Cech TR
Genes Dev; 2019 Oct; 33(19-20):1416-1427. PubMed ID: 31488576
[TBL] [Abstract][Full Text] [Related]
6. The deletion of the protein phosphatase 1 regulator NIPP1 in testis causes hyperphosphorylation and degradation of the histone methyltransferase EZH2.
Ferreira M; Verbinnen I; Fardilha M; Van Eynde A; Bollen M
J Biol Chem; 2018 Nov; 293(47):18031-18039. PubMed ID: 30305391
[TBL] [Abstract][Full Text] [Related]
7. The oncogenic polycomb histone methyltransferase EZH2 methylates lysine 120 on histone H2B and competes ubiquitination.
Kogure M; Takawa M; Saloura V; Sone K; Piao L; Ueda K; Ibrahim R; Tsunoda T; Sugiyama M; Atomi Y; Nakamura Y; Hamamoto R
Neoplasia; 2013 Nov; 15(11):1251-61. PubMed ID: 24339737
[TBL] [Abstract][Full Text] [Related]
8. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
[TBL] [Abstract][Full Text] [Related]
9. O-GlcNAcylation regulates EZH2 protein stability and function.
Chu CS; Lo PW; Yeh YH; Hsu PH; Peng SH; Teng YC; Kang ML; Wong CH; Juan LJ
Proc Natl Acad Sci U S A; 2014 Jan; 111(4):1355-60. PubMed ID: 24474760
[TBL] [Abstract][Full Text] [Related]
10. Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background.
Gall Trošelj K; Novak Kujundzic R; Ugarkovic D
Clin Epigenetics; 2016; 8():55. PubMed ID: 27239242
[TBL] [Abstract][Full Text] [Related]
11. Weaver Syndrome-Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In Vitro.
Cohen AS; Yap DB; Lewis ME; Chijiwa C; Ramos-Arroyo MA; Tkachenko N; Milano V; Fradin M; McKinnon ML; Townsend KN; Xu J; Van Allen MI; Ross CJ; Dobyns WB; Weaver DD; Gibson WT
Hum Mutat; 2016 Mar; 37(3):301-7. PubMed ID: 26694085
[TBL] [Abstract][Full Text] [Related]
12. The noncanonical role of EZH2 in cancer.
Huang J; Gou H; Yao J; Yi K; Jin Z; Matsuoka M; Zhao T
Cancer Sci; 2021 Apr; 112(4):1376-1382. PubMed ID: 33615636
[TBL] [Abstract][Full Text] [Related]
13. Non-canonical transcriptional regulation of INHAT subunit SET/TAF-Iβ by EZH2.
Hwang IJ; Park J; Seo SB
Biochem Biophys Res Commun; 2022 Dec; 635():136-143. PubMed ID: 36274363
[TBL] [Abstract][Full Text] [Related]
14. The roles of EZH2 in cancer and its inhibitors.
Liu Y; Yang Q
Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376
[TBL] [Abstract][Full Text] [Related]
15. EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair.
Koyen AE; Madden MZ; Park D; Minten EV; Kapoor-Vazirani P; Werner E; Pfister NT; Haji-Seyed-Javadi R; Zhang H; Xu J; Deng N; Duong DM; Pecen TJ; Frazier Z; Nagel ZD; Lazaro JB; Mouw KW; Seyfried NT; Moreno CS; Owonikoko TK; Deng X; Yu DS
Oncogene; 2020 Jun; 39(25):4798-4813. PubMed ID: 32457468
[TBL] [Abstract][Full Text] [Related]
16. Polycomb Repressive Complex 2 in Oncology.
Guo Y; Yu Y; Wang GG
Cancer Treat Res; 2023; 190():273-320. PubMed ID: 38113005
[TBL] [Abstract][Full Text] [Related]
17. EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition.
Romero P; Richart L; Aflaki S; Petitalot A; Burton M; Michaud A; Masliah-Planchon J; Kuhnowski F; Le Cam S; Baliñas-Gavira C; Méaudre C; Luscan A; Hamza A; Legoix P; Vincent-Salomon A; Wassef M; Holoch D; Margueron R
Nat Commun; 2024 Apr; 15(1):3452. PubMed ID: 38658543
[TBL] [Abstract][Full Text] [Related]
18. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer.
Tang B; Sun R; Wang D; Sheng H; Wei T; Wang L; Zhang J; Ho TH; Yang L; Wei Q; Huang H
Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33593912
[TBL] [Abstract][Full Text] [Related]
19. Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance.
Brooun A; Gajiwala KS; Deng YL; Liu W; Bolaños B; Bingham P; He YA; Diehl W; Grable N; Kung PP; Sutton S; Maegley KA; Yu X; Stewart AE
Nat Commun; 2016 Apr; 7():11384. PubMed ID: 27122193
[TBL] [Abstract][Full Text] [Related]
20. EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma.
Hübner JM; Müller T; Papageorgiou DN; Mauermann M; Krijgsveld J; Russell RB; Ellison DW; Pfister SM; Pajtler KW; Kool M
Neuro Oncol; 2019 Jul; 21(7):878-889. PubMed ID: 30923826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
